This company has been acquired
Vapotherm Past Earnings Performance
Past criteria checks 0/6
Vapotherm's earnings have been declining at an average annual rate of -10.3%, while the Medical Equipment industry saw earnings growing at 11.4% annually. Revenues have been declining at an average rate of 0.4% per year.
Key information
-10.3%
Earnings growth rate
9.4%
EPS growth rate
Medical Equipment Industry Growth | 8.9% |
Revenue growth rate | -0.4% |
Return on equity | n/a |
Net Margin | -76.7% |
Last Earnings Update | 30 Jun 2024 |
Recent past performance updates
Recent updates
Vapotherm announces $23M private placement
Feb 08Vapotherm GAAP EPS of -$0.98 misses by $0.20, revenue of $13.5M misses by $3.02M
Nov 02Vapotherm draws downgrade at William Blair after 2Q results
Aug 04Vapotherm: Out Of Air
May 11Is Vapotherm (NYSE:VAPO) Using Too Much Debt?
Jan 24Vapotherm: Hardly Breathing Room
Jul 11Health Check: How Prudently Does Vapotherm (NYSE:VAPO) Use Debt?
May 10Vapotherm reports Q1 results
May 05The Independent Director of Vapotherm, Inc. (NYSE:VAPO), Anthony Arnerich, Just Bought 59% More Shares
Mar 12Announcing: Vapotherm (NYSE:VAPO) Stock Increased An Energizing 225% In The Last Year
Mar 11Does Vapotherm (NYSE:VAPO) Have A Healthy Balance Sheet?
Jan 19Vapotherm guides Q4 revenue above consensus, ~212% Y/Y growth
Jan 13Thomas Smith of Vapotherm, Inc. (NYSE:VAPO) Just Spent US$217k On Shares
Dec 14Investors Who Bought Vapotherm (NYSE:VAPO) Shares A Year Ago Are Now Up 132%
Dec 11Vapotherm shares +9% on higher Q4 guidance
Dec 01Vapotherm: The Game Has Completely Changed
Nov 13Revenue & Expenses Breakdown
How Vapotherm makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
Date | Revenue | Earnings | G+A Expenses | R&D Expenses |
---|---|---|---|---|
30 Jun 24 | 71 | -54 | 45 | 13 |
31 Mar 24 | 70 | -55 | 48 | 14 |
31 Dec 23 | 69 | -58 | 52 | 14 |
30 Sep 23 | 68 | -69 | 58 | 15 |
30 Jun 23 | 66 | -81 | 65 | 17 |
31 Mar 23 | 63 | -108 | 68 | 19 |
31 Dec 22 | 67 | -113 | 75 | 20 |
30 Sep 22 | 70 | -110 | 80 | 21 |
30 Jun 22 | 95 | -98 | 89 | 20 |
31 Mar 22 | 103 | -72 | 94 | 19 |
31 Dec 21 | 113 | -60 | 93 | 18 |
30 Sep 21 | 132 | -58 | 99 | 18 |
30 Jun 21 | 124 | -57 | 92 | 19 |
31 Mar 21 | 139 | -48 | 92 | 19 |
31 Dec 20 | 126 | -52 | 89 | 17 |
30 Sep 20 | 98 | -47 | 76 | 16 |
30 Jun 20 | 78 | -47 | 67 | 14 |
31 Mar 20 | 55 | -52 | 60 | 13 |
31 Dec 19 | 48 | -51 | 56 | 13 |
30 Sep 19 | 47 | -51 | 54 | 12 |
30 Jun 19 | 45 | -48 | 51 | 11 |
31 Mar 19 | 44 | -47 | 49 | 10 |
31 Dec 18 | 42 | -43 | 45 | 9 |
30 Sep 18 | 41 | -39 | 42 | 8 |
30 Jun 18 | 40 | -37 | 39 | 8 |
31 Mar 18 | 38 | -33 | 36 | 8 |
31 Dec 17 | 36 | -31 | 34 | 8 |
31 Dec 16 | 30 | -23 | 26 | 6 |
Quality Earnings: VAPO is currently unprofitable.
Growing Profit Margin: VAPO is currently unprofitable.
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Earnings Trend: VAPO is unprofitable, and losses have increased over the past 5 years at a rate of 10.3% per year.
Accelerating Growth: Unable to compare VAPO's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: VAPO is unprofitable, making it difficult to compare its past year earnings growth to the Medical Equipment industry (7.2%).
Return on Equity
High ROE: VAPO's liabilities exceed its assets, so it is difficult to calculate its Return on Equity.
Return on Assets
Return on Capital Employed
Discover strong past performing companies
Company Analysis and Financial Data Status
Data | Last Updated (UTC time) |
---|---|
Company Analysis | 2024/09/19 22:39 |
End of Day Share Price | 2024/09/19 00:00 |
Earnings | 2024/06/30 |
Annual Earnings | 2023/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
Package | Data | Timeframe | Example US Source * |
---|---|---|---|
Company Financials | 10 years |
| |
Analyst Consensus Estimates | +3 years |
|
|
Market Prices | 30 years |
| |
Ownership | 10 years |
| |
Management | 10 years |
| |
Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
Vapotherm, Inc. is covered by 5 analysts. 0 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
Analyst | Institution |
---|---|
Robert Hopkins | BofA Global Research |
Michael Gorman | BTIG |
William Plovanic | Canaccord Genuity |